Abstract. Cancer still imposes a global threat to public health. After decades of research on cancer biology and enormous efforts in developing anticancer therapies, we now understand that the majority of cancers can be prevented. Bioactive phytochemicals present in edible plants have been shown to reduce the risk of various types of cancer. Ginseng (Panax ginseng C.A. Meyer), which contains a wide variety of sapo-

Contents

1. Ginsenosides: the ginseng saponins
2. Ginsenosides in the prevention and therapy of cancer
3. Biochemical basis of anticancer properties of selected
ginsenosides
4. Future perspectives

1. Ginsenosides: the ginseng saponins

Ginseng (Panax ginseng C.A. Meyer) is widely used as a compo-

Key words: ginsenosides, chemoprevention, chemosensitization, cell signaling

Correspondence to: Dr Joydeb Kumar Kundu, College of Pharmacy, Keimyung University, 2800 Dalgubeodaero, Dalseo-gu, Daegu 704-701, Republic of Korea
E-mail: kundukj@yahoo.com; kundukj@kmu.ac.kr

*Contributed equally

DOI: 10.3892/ijmm.2013.1519

Received July 9, 2013; Accepted September 26, 2013

1College of Life Sciences and Biotechnology, Korea University, Seoul 136-701;
2College of Pharmacy, Keimyung University, Daegu 704-701, Republic of Korea

15-809
Since the structure of ginsenoside Rg1 from the mixture of ginseng saponins has been reported in 1971, >30 ginsenosides have been found in the roots and other parts of Panax ginseng, and a total of >60 ginsenosides have been isolated from members of the Panax genus. Chemical structures of several common ginsenosides are presented in Fig. 1. The substituents (R1, R2 and R3) in Fig. 1A for selected ginsenosides are listed in Table I. In general, the ginseng saponins can be divided according to the structure of the aglycone component of the molecule: i) the oleanolic acid type, such as ginsenoside Rg1; ii) the 20(S)-protopanaxadiol type, such as ginsenosides Ra, Rb, Rc, Rd, Rg3, Rh2 and Rs; and iii) the 20(S)-protopanaxatriol type, such as ginsenosides Re, Rf, Rg1, Rg2 and Rh1 (2,5,6). The detailed chemistry and the structure-activity relationship of diverse classes of ginsenosides have been reviewed elsewhere (6-8) and is beyond the scope this article. The aim of this review was limited to the biochemistry behind the anticancer activity of ginsenosides.

2. Ginsenosides in the prevention and therapy of cancer

The anticancer properties of ginsenosides have been extensively investigated over the past several decades. Ginsenosides have been shown to elicit chemopreventive and chemotherapeutic effects in a wide range of animal models of experimental carcinogenesis (5,8-10) (Table II). For instance, the topical application of Rg3 on to the shaven backs of female ICR mice has been shown to inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ornithine decarboxylase activity and 7,12-dimethylbenz[a]anthracene (DMBA)-initiated papilloma formation (11). Likewise, the oral administration of ginsenoside Rp1 at the pre-, peri- and post-initiation stage, has been shown to significantly reduce the incidence and the multiplicity of chemically-induced mouse skin papillomas (12). As previously demonstrated, the water extract of Korean red ginseng attenuated the development of testosterone-induced benign prostate hyperplasia, a pre-neoplastic condition that progresses to malignant prostate cancer (13).

The inhibitory effects of various ginsenosides on the growth of different cancer cell xenograft tumors have been reported. For example, treatment with Rg3 has been shown to inhibit the growth of human colon cancer (HCT-116) cell xenograft tumors in nude mice (14). The administration of Rg3 alone or in combination with gemcitabine, has also significantly inhibited the growth of Lewis lung carcinoma cells implanted into C57BL/6 mice by suppressing tumor angiogenesis (15). The oral administration of Rh2 has been shown to reduce human prostate cancer (PC3) cell tumor growth in nude mice (16). Likewise, as previously demonstrated, the growth of human gastric cancer (SGC7901) cells in nude mice was diminished by compound K, an intestinal metabolite of ginsenoside Rb1, Rb2 and Rc (17). A previous study revealed that 25-methoxy-protopanaxadiol reduced the growth of human lung cancer (A549) cell tumor xenografts in nude mice (18). Similarly, 25-methoxy-protopanaxadiol and 25-hydroxy-protopanaxadiol have been shown to inhibit pancreatic cancer cell xenograft tumor growth in vivo and to reduce the proliferative ability of these cells in vitro (19). Treatment with 20(S)-25-methoxy-dammarane-3β, 12β, 20-triol, a newly identified ginsenoside from Panax notoginseng, has been shown to decrease the growth of human breast cancer (MCF-7 and MDA-MB-231) cell tumor xenografts in nude mice (20). As previously shown,

<table>
<thead>
<tr>
<th>Ginsenosides</th>
<th>R1</th>
<th>R2</th>
<th>R3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ra1</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>Xyl-Ara(f)-Glc-</td>
</tr>
<tr>
<td>Ra2</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>Xyl-Ara(f)-Glc-</td>
</tr>
<tr>
<td>Rb1</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>Glc-Glc-</td>
</tr>
<tr>
<td>Rb2</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>Ara(p)-Glc-</td>
</tr>
<tr>
<td>Rc</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>Ara(f)-Glc-</td>
</tr>
<tr>
<td>Rd</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>Glc-</td>
</tr>
<tr>
<td>Re</td>
<td>H</td>
<td>Rha-Glc-O-</td>
<td>Glc-</td>
</tr>
<tr>
<td>Rf</td>
<td>H</td>
<td>Glc-Glc-O-</td>
<td>Glc-</td>
</tr>
<tr>
<td>Rg1</td>
<td>H</td>
<td>Glc-O-</td>
<td>H</td>
</tr>
<tr>
<td>Rg2</td>
<td>H</td>
<td>Rha-Glc-O-</td>
<td>H</td>
</tr>
<tr>
<td>Rg3</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>Rh1</td>
<td>H</td>
<td>Glc-O-</td>
<td>H</td>
</tr>
<tr>
<td>Rh2</td>
<td>Glc-</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>Rp1</td>
<td>Glc-Glc-</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>Rs3</td>
<td>AcGlu-Glu-</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>Compound K</td>
<td>H</td>
<td>H</td>
<td>Glc-</td>
</tr>
</tbody>
</table>

Glc, glucopyranoside; Ara(f), arabinofuranose; Ara(p), arabinopyranoside; Rha, rhamnopyranoside.
Over the past several decades, enormous efforts have been made to elucidate the biochemistry behind the anticancer properties of various ginsenosides. The major mechanisms of the anticarcinogenic effects of ginsenosides include: i) the inhibition of oxidative damage and inflammation; ii) the inhibition of tumor cell proliferation; iii) the induction of cancer cell apoptosis.

Table II. Inhibitory effects of ginsenosides on the development and growth of tumors in vivo.

<table>
<thead>
<tr>
<th>Ginsenosides</th>
<th>Animal model</th>
<th>Mechanisms/effects</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rp1</td>
<td>DMBA-initiated and croton oil-promoted skin papillomagenesis in Swiss albino mice</td>
<td>↓ Tumor incidence and multiplicity, ↑ Lipid peroxidation, ↑ Activity of microsomal enzymes, ↑ Activity of SOD, GPx, GR and GST, ↑ Level of reduced glutathione</td>
<td>(12)</td>
</tr>
<tr>
<td>Rg3</td>
<td>DMBA-initiated and TPA-promoted skin papillomagenesis in female ICR mice</td>
<td>↓ Average number of skin tumors, ↓ Ornithine decarboxylase activity, ↑ Expression of COX-2, ↑ Activation of NF-κB and AP-1</td>
<td>(11)</td>
</tr>
<tr>
<td>Rg3</td>
<td>HCT-116 cells xenograft tumor in nude mice</td>
<td>↓ Xenograft tumor growth, ↑ Expression of PCNA, ↑ Nuclear staining of β-catenin, β-catenin/TCF-mediated transcriptional activity</td>
<td>(14)</td>
</tr>
<tr>
<td>Rp1 alone or with gemcitabine</td>
<td>Lewis lung cancer xenografts in syngenic C57BL/6 mice</td>
<td>↓ Tumor growth, ↑ VEGF expression, ↑ Survival of tumor-bearing mice</td>
<td>(15)</td>
</tr>
<tr>
<td>Rg3</td>
<td>Administration of SKOV-3 cells via lateral tail vein and intraperitoneal administration of Rg3 daily for 20 days from the day of tumor inoculation. Intradermal injection of SKOV-3 cells to mice and treatment with Rg3 daily for five days after tumor inoculation</td>
<td>↓ Tumor angiogenesis in SKOV-3 cell xenograft tumors</td>
<td>(80)</td>
</tr>
<tr>
<td>Rg3 alone or with cyclophosphamide</td>
<td>Human ovarian cancer cell xenografts in nude mice</td>
<td>↓ Tumor growth, ↑ Expression of PCNA and VEGF, ↑ Microvessel density</td>
<td>(73)</td>
</tr>
<tr>
<td>Water extract containing 20(s)-Rg3</td>
<td>Testosterone-induced benign prostate hyperplasia in rats and prostate cell growth</td>
<td>↑ Thickening of prostate epithelium, ↑ AR activity, ↑ Proliferation of prostate cells</td>
<td>(13)</td>
</tr>
<tr>
<td>Rb2</td>
<td>B16-BL6 melanoma xenograft tumor in nude mice (intratumoral or oral administration of Rb2)</td>
<td>↑ Tumor angiogenesis and growth</td>
<td>(76)</td>
</tr>
<tr>
<td>Rh2</td>
<td>MDA-MB-231 cell xenografts in nude mice (Rh2 given by oral gavage)</td>
<td>↑ Tumor growth, ↑ Intratumoral apoptotic bodies, ↑ Proliferation index</td>
<td>(46)</td>
</tr>
<tr>
<td>M1</td>
<td>Lewis lung carcinoma in syngenic C57BL/6 mice</td>
<td>↓ Lung metastasis</td>
<td>(88)</td>
</tr>
<tr>
<td>Compound K</td>
<td>Gastric cancer (SGC7901) cell tumor xenografts in athymic nude mice</td>
<td>↓ Tumor volume and weight, ↑ Expression of Bid and MMP-9 in xenograft tumors and in liver</td>
<td>(17)</td>
</tr>
</tbody>
</table>

DMBA, 7,12-dimethylbenz[a]anthracene; TPA, 12-O-tetradecanoylphorbol-13-acetate; SOD, superoxide dismutase; GPx, glutathione peroxidase; GR, glutathione reductase; GST, glutathione-S-transferase; COX-2, cyclooxygenase-2; NF-κB, nuclear factor-κB; PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor; AR, androgen receptor.

25-hydroxy-protopanaxadiol, but not 25-hydroxy-protopanaxatriol, inhibited PC3 cell xenograft tumor growth (21).
cell apoptosis; iv) anti-angiogenic activity; v) inhibition of the invasion and metastasis of tumor cells; and vi) the enhancement of the sensitivity of resistant cells to chemotherapeutic agents (Fig. 2).

3. Biochemical basis of anticancer properties of selected ginsenosides

**Antioxidant activity.** The oxidative stress-induced damage of cellular macromolecules, such as proteins, nucleic acids and lipids contributes to the neoplastic transformation of cells. Whereas oxidative stress-induced tissue damage precipitates a state of local tissue inflammation, persistent inflammation triggers the generation of reactive oxygen species (ROS) and reactive nitrogen species. A wide variety of antioxidant and anti-inflammatory phytochemicals have been reported to possess anticancer properties. Although it is generally accepted that the bioactivity of ginsenosides is due to their ability to reduce oxidative stress and inflammation, there have been limited studies unraveling the molecular mechanisms of the antioxidant and anti-inflammatory activity of individual ginsenosides. In general, ginsenosides scavenge ROS and induce the expression and activity of various antioxidant and/or detoxification enzymes. For instance, Rb1 has been reported to protect plasmid DNA from damage by the direct scavenging of \( \cdot \)OH, which can bind to the double bond on the side chain of Rb1, as well as hydrogen atoms adjacent to the \( \cdot \)OH group, including those of sugar moieties. Rb1 has also elicited high reactivity to hypochlorous acid (HOCl), a neutrophilic oxidant with mutagenic potential, effectively inhibiting HOCl-induced tyrosine chlorination in a cell free system (22). Ginsenosides Rg3 and Rh2 have been shown to reduce the ethanol-induced generation of ROS in mouse hepatocyte cells (23).

Ginsenosides have been reported to activate several antioxidant enzymes, which are transcriptionally regulated to a great extent by factors, such as nuclear factor erythroid-derived 2-like 2 (Nrf2), nuclear factor-κB (NF-κB), or activator protein (AP)-1 or -2. As previously demonstrated, 20(s)-protopanaxadiol, but not total saponins or 20(s)-protopanaxatriol, induced the expression of superoxide dismutase (SOD), possibly by increasing the AP2 transcription factor activity (24). Among the protopanaxadiols, Rb2 has been shown to significantly induce the expression of genes encoding antioxidant enzymes, such as SOD and catalase in vitro (25). Ginsenoside Rd has been shown to elevate intracellular glutathione levels by increasing the AP2 transcription factor activity (26). As previously demonstrated, the induction of heme oxygenase-1 (HO-1) by ginsenoside 20(s)-protopanaxadiol inhibited the activation of inflammatory signaling molecules in murine RAW 264.7 macrophages stimulated with lipopolysaccharide (LPS) (27). The co-treatment of macrophages with HO-1 inhibitor abolished the inhibitory effects of this ginsenoside on the expression of inducible nitric oxide (NO) synthase (iNOS) and the activation of NF-κB (27). On the other hand, the treatment of HepG2 cells with Rb1, Rg1 or 20(s)-protopanaxatriol, or with a combination of 20(s)-protopanaxatriol with Rb1 or Rg1 has been shown to enhance the binding of Nrf2 to antioxidant response element (ARE), thereby increasing the total antioxidant activity (28). A previous study revealed that the treatment of Swiss albino mice with ginsenoside Rp1 for seven days by gavage significantly elevated the levels of skin microsomal cytochrome p-450 and cytochrome b5 and glutathione-S-transferase (GST), and reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), DT-diaphorase, SOD and catalase levels, resulting in the enhanced detoxification of carcinogens and the reduction of oxidative stress (12).

**Anti-inflammatory effects.** Since chronic inflammation contributes to the development and progression of tumors, the suppression of inflammatory signaling is a rational approach for cancer prevention and therapy. The anticancer
activities of many phytochemicals have been linked to their anti-inflammatory effects. Several ginsenosides have been reported to interfere with inflammatory signaling, thereby inhibiting tumor promotion and progression (8, 9). The topical application of ginsenoside Rg3 has been shown to attenuate the TPA-induced activation of NF-κB and AP-1, and the expression of the pro-inflammatory enzyme, cyclooxygenase-2 (COX-2), accounting for its anti-tumor promoting effects in chemically-induced mouse skin carcinogenesis (11). As previously demonstrated, 20(S)-Rg3, a predominant stereospecific form of Rg3, inhibited the generation of ROS, but not that of NO, and decreased the production of cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and that of prostaglandin E2 (PGE2) in LPS-stimulated Raw 264.7 murine macrophages (29). Treatment with Rg3 also attenuated the LPS-induced expression of COX-2 in macrophages and reduced TNF-α-induced matrix metalloproteinase (MMP)-9 activity in human keratinocyte (HaCaT) cells (29). Ginsenoside Rg5 has also been shown to attenuate LPS-induced lung inflammation in mice through the down-regulation of NF-κB activity. Rg5 reduced the expression of pro-inflammatory mediators, such as COX-2, iNOS, IL-1β and TNF-α in LPS-stimulated alveolar macrophages by blocking the activities of IL-1 receptor-associated kinases (IRAKs) and IκB kinase-β (IKKβ), and subsequently inhibiting the phosphorylation and nuclear accumulation of NF-κB (30). Ginsenoside Rbl and its intestinal metabolite, compound K, also function through a similar mechanism in LPS-induced cytokine production in murine peritoneal macrophages. These ginseng saponins have been shown to inactivate IRAK1, IKKβ, NF-κB and mitogen-activated protein (MAP) kinases (31). Moreover, the administration of Rbl or compound K by gavage attenuated 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice by inhibiting colonic myeloperoxidase activity, decreasing the expression of COX-2, iNOS, TNF-α, IL-1β and IL-6 through the inactivation of NF-κB (31). Likewise, the oral administration of ginsenoside Rd to rats attenuated TNBS-induced colitis by inhibiting myeloperoxidase activity and preventing the production of cytokines, such as TNF-α, IL-1β and IL-6 through the blockade of p38 MAP kinase and c-Jun-N-terminal kinase (JNK) (32).

In previous studies, the treatment of Raw 264.7 macrophages with either Rbl (33) or the ginseng metabolites, compound K (33) or 20(s)protopanaxatriol (34), diminished the LPS-induced expression of COX-2 and iNOS by blocking the activation of NF-κB. Of note, the mutation of either NF-κB or CRE-binding sequences in the COX-2 promoter did not alter the inhibitory effects of Rbl on TPA-induced COX-2 promoter activity; however, the effects were abrogated upon the mutation of NF-κB binding sites. These findings suggest that NF-κB, but not NF-κB, is a target of Rbl in suppressing COX-2 expression. In a recent study, Huang et al (35) demonstrated that Rgl blocked the activation of transient receptor potential vanilloid-1 (TRPV1) and inhibited the transcriptional activity of NF-κB, thereby suppressing the expression of COX-2, the production of PGE2 and the secretion of IL-8 in capsaicin-stimulated HaCaT keratinocytes, as well as in TRPV1-overexpressing human embryonic kidney (HEK)-293 cells (35). Likewise, co-treatment with ginsenoside Rbl has been shown to diminish capsaicin-induced NF-κB transcriptional activity and reduce the release of IL-8 and PGE2 in HaCaT keratinocytes by blocking the activation of TRPV1 (36).

Inhibition of proliferation and induction of apoptosis in cancer cells. The anti-proliferative and apoptotic effects of a wide variety of ginsenosides have been extensively investigated. The mechanisms by which selected ginsenosides inhibit proliferation and induce apoptosis in various cancer cells are discussed in this section.

Rg3. Several ginsenosides of the Rg series have been reported to inhibit proliferation and induce apoptosis in various cancer cells in culture. In a previous study, the treatment of human prostate cancer (LNCaP) cells with ginsenoside Rg3 reduced cell proliferation through G1 phase cell cycle arrest, which was associated with the decreased expression of the cyclin-dependent kinase (Cdk) inhibitors, p21 and p27 (37). The authors demonstrated that Rg3 also attenuated the expression of prostate-specific antigen (PSA), androgen receptor (AR), 5α-reductase and proliferating cell nuclear antigen (PCNA). Moreover, Rg3 induced apoptosis in these cells by inhibiting Bcl-2 expression and inducing caspase-3 activity (37). Bae et al (13) recently demonstrated that Rg3 decreased the AR activity through the proteasomal degradation of AR and inhibited androgen-induced benign prostate hyperplasia in rats. Rg3 has also been shown to inhibit the expression of Bcl-2 and Bcl-xL, and induce the expression of Bax, resulting in reduced mitochondrial membrane potential, cytochrome c release and the activation of caspase-3, thereby inducing apoptosis in human hepatocellular carcinoma cells (38-40) and human colon cancer (HT-29) cells (41). A recent study demonstrated that Rg3 sensitized several liver cancer (HepG2, SK-Hepl, Huh-7 and Hep3B) cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, but did not affect the survival of normal hepatocytes. The enhancement of TRAIL-sensitivity and the subsequent induction of cell death was mediated through the upregulation of death receptor-5 (DR5) through the activation of an endoplasmic reticulum (ER)-stress protein CCAAT/enhancer binding protein (C/EBP) homology protein (CHOP), which is also known as growth arrest- and DNA damage-inducible gene 153 (GADD153) (42). The Rg3-induced activation of cyclic-AMP-activated protein kinase (AMPK) accounted for its apoptotic effects in HT-29 cells, as the co-treatment of cells with Rg3 in the presence of the AMPK inhibitor, compound C, or in cells transfected with AMPK-siRNA, abrogated Rg3-induced apoptosis (41). According to a recent study, Rg3 inhibited the growth and survival of human gastric cancer (AGS) cells by blocking the activity of the transient receptor potential melastatin-7 (TRPM7) channel. Rg3-mediated sub-G1 arrest, the cleavage of poly(ADP-ribose) polymerase (PARP) and the activation of caspases were abolished when AGS cells were co-treated with chemical inhibitors of TRPM7 (43). Chen et al (44) reported that Rg3 inhibited cell proliferation by blocking cell cycle progression and inducing apoptosis in B16 melanoma cells. Rg3 attenuated the proliferation of HCT116 cells in culture, at least in part, by decreasing the nuclear localization of β-catenin and downregulating β-catenin/T cell factor (TCF)-mediated transcriptional activity (44).

Rh2. Ginsenoside Rh2 has exhibited significantly more potent cell death activity than ginsenoside Rg3 in HCT-116 and SW-480 colorectal cancer cells through the generation
Recent studies have demonstrated that Rh2 inhibits cancer cell cholesterol overloading or transfection with FAS siRNA (56). In independent oligomerization of FAS, which was abrogated by internalization of caveolin-1 and GM1, followed by the ligand- and chemical properties of membrane lipid rafts through the shown to induce apoptosis through the disruption of physical result in the inactivation of cyclin D1, E and A, and increasing the expression of p21 without affecting the levels of p53 or serine-15 phosphorylated p53. In addition, prolonged incubation with Rpl1 activated caspase-3, -8 and -9 by stimulating the mitochondrial release of cytochrome c through the activation of Bax and Bid, and the subsequent loss of mitochondrial membrane potential. This led to the Rpl1-induced cleavage of PARP and the induction of apoptosis in HeLa cells (61).

Rk1. Ginsenoside Rk1 is a major bioactive component of heat-processed ginseng. The concentration- and time-dependent cytotoxic effects of Rk1 in human melanoma (SK-MEL2) cells have been shown to be associated with the upregulation of Fas, FasL and Bax protein and the downregulation of procaspase-8 and -9, mutant p53 and Bcl-2 protein expression (62). Likewise, the activation of caspase-3 and -8 by Rk1 induced apoptosis in HepG2 cells (63).

Others. Kim et al (64) reported that a diol-type ginseng saponin Rs3 induced cell cycle arrest at the G1/S boundary in SK-HEP-1 cells by increasing the expression of cyclin D1, E and the cleavage of PARP (10). In a previous study, the pro-apoptotic effects of Rh2 in SK-HEP1 cells were mediated by the caspase-3-dependent activation of protein kinase C-δ (PKC-δ). The treatment of cells with caspase-3 inhibitor attenuated Rh2-induced proteolytic cleavage and the activation of PKC-δ. The blockade of caspase-3 activity or the pharmacological inhibition of PKCδ abolished Rh2-induced apoptosis in these cells (53). Moreover, the generation of ROS, the activation of JNK1, the depolarization of mitochondrial membrane potential and the subsequent activation of caspase-3 have been shown to be associated with Rh2-induced apoptosis in HeLa cells, which were abrogated by the overexpression of catalase or treatment with N-acetyl cysteine (NAC) (54).

Another mechanism of Rh2-induced apoptosis in cancer cells involves the disruption of membrane lipid rafts, thereby resulting in the inactivation of Akt signaling and the subsequent inhibition of Bad phosphorylation and the increased expression of the pro-apoptotic proteins, Bim and Bax, in MDA-MB-231 cells (55). The treatment of HeLa cells with Rh2 has been shown to induce apoptosis through the disruption of physical and chemical properties of membrane lipid rafts through the internalization of caveolin-1 and GM1, followed by the ligand-independent oligomerization of FAS, which was abrogated by cholesterol overloading or transfection with FAS siRNA (56). Recent studies have demonstrated that Rh2 inhibits cancer cell proliferation and induces apoptosis by modulating the function of certain micro-RNAs (miRs) (57,58). For example, the miR array analysis of Rh2-treated human glioma (U251) cells revealed the upregulation of 14 miRs and the downregulation of 12 miRs. Transfection with miR-128 inhibitor prevented the overexpression of miR-128 in Rh2-treated U251 cells and blunted Rh2-induced apoptosis by blocking the activation of caspase-3 and the transcriptional activation of the miR-128 target gene, E2F3a (58).

Rpl1. Rpl1 is semi-synthesized from crude ginsenosides (59). The incubation of human breast cancer cells with ginsenoside Rpl1 has been shown to attenuate anchorage-dependent and -independent colony formation, which was associated with the reduced stability of insulin-like growth factor receptor (60). In a previous study, Rpl1 induced G1 phase arrest in HeLa cells by inhibiting the expression of cyclin D1, E and A, and increasing the expression of p21 without affecting the levels of p53 or serine-15 phosphorylated p53. In addition, prolonged incubation with Rpl1 activated caspase-3, -8 and -9 by stimulating the mitochondrial release of cytochrome c through the activation of Bax and Bid, and the subsequent loss of mitochondrial membrane potential. This led to the Rpl1-induced cleavage of PARP and the induction of apoptosis in HepG2 cells (63).
and VEGF (73). Zhang et al. (74) also demonstrated that in the presence of Rg3, a low dose of cyclophosphamide was effective in suppressing the growth of Lewis lung carcinoma cells by inhibiting angiogenesis.

Endothelial progenitor cells (EPCs) appear to play a key role in the growth of early tumors. In a recent study, Kim et al. (75) demonstrated that the treatment of ex vivo cultured endothelial cells, a type of EPCs, with Rg3 inhibited proliferation, migration and tubular formation by blocking the VEGF-dependent activation of ERK and p38 MAP kinases and inhibiting the mobilization of EPCs from the bone marrow microenvironment to the peripheral circulation. The intratumoral or oral administration of another ginsenoside Rb2 has been shown to inhibit tumor angiogenesis in a model of B16-BL6 melanoma cell xenografts in nude mice. However, the intravenous administration of Rb2 failed to inhibit the growth of xenograft tumors. Moreover, Rb2 did not affect the growth of rat lung endothelial cells, B16-BL6 melanoma cells or various types of murine normal cells in vitro (76). Compound K significantly inhibited the migration and tube formation in basic fibroblast growth factor (bFGF)-treated HUVECs and reduced the secretion of VEGF and increased the production of pigment epithelium-derived factor. Moreover, compound K attenuated the phosphorylation of p38 MAP kinase and Akt in bFGF-stimulated HUVECs, and inhibited neovascularization in the Matrigel plugs excised from mice in vivo (77).

**Attenuation of invasion and metastasis.** Incubation with Rg3 has been shown to reduce the migration of highly metastatic prostate cancer (PC3M) cells by downregulating the expression of aquaporin-1 (AQP1), a water channel protein that has been implicated in cell migration, through the blockade of p38 MAP kinase phosphorylation. The inhibitory effects of Rg3 on the migration of these cells were annulled either by the overexpression of AQP1 or by the pharmacological inhibition of p38 MAP kinase (78). Ginsenosides Rg3 and Rb2 have been shown to significantly inhibit the adhesion of B16-BL6 melanoma cells to fibronectin and laminin, and attenuate the invasion of these cells into the reconstituted basement membrane in a dose-dependent manner. Moreover, the lung metastasis of B16-BL6 or colon 26-M3.1 cells in nude mice was significantly inhibited by the intravenous or oral administration of Rg3 or Rb2 (79). Likewise, treatment with Rg3 has been shown to markedly reduce the expression of MMP-9 and decrease the invasive and metastatic ability (metastasis to lungs) of SKOV-3 cells in mice (80). Moreover, a previous study demonstrated that the intraperitoneal administration of Rg3 prevented the metastasis (to the lungs) of B16 melanoma cells (44).

In another study, treatment with Rg3 elicited a decreased expression of chemokine receptor CXCR4 in MDA-MB-231 cells and reduced chemokine CXCL12-induced migration of these cells (81). Although Rg3 failed to affect bombesin-induced intestinal carcinogenesis, the ginsenoside significantly decreased the peritoneal metastasis of intestinal adenocarcinomas (82). Rg3 has also been shown to inhibit the invasion of rat ascites hepatoma cells (MM1), B16F10 melanoma cells, human small cell lung carcinoma and human pancreatic adenocarcinoma cells in a cell monolayer invasion assay (83). Moreover, Rg3 attenuated experimental pulmonary metastasis by highly metastatic mouse melanoma (B16F10)
cells. The authors demonstrated that Rg2 and Rb2 mildly inhibited invasion, but Rh1, Rh2, Rbl, Re or Re had no effect on the invasive ability of these cells (83). By contrast, ginsenoside Rh1 (84) and Rd (85) suppressed the invasion and metastasis of human hepatocellular carcinoma HepG2 cells. According to the former study, Rh1 inhibited the mRNA expression and the promoter activity of MMP-1 by blocking the activation of MAP kinases, such as ERK, p38 MAP kinase and JNK. In addition, Rh1 diminished the phorbol ester-induced expression of c-Jun and c-Fos, but failed to affect the DNA binding of AP-1 in HepG2 cells (84). Treatment with ginsenoside Rd had been shown to prevent the invasion and migration of HepG2 cells by downregulating the expression of MMP-1, MMP-2 and MMP-7, by blocking the phosphorylation of ERK and p38 MAP kinase and by inhibiting the activation of AP-1 (85). Likewise, ginsenoside Rb2 had been shown to inhibit phorbol ester-induced MMP-9 mRNA expression and diminish the invasion of astrogliaoma cells by blocking the activation of NF-κB and AP-1 through the inhibition of p38 MAP kinase, ERK and JNK phosphorylation (86). Rpl markedly inhibited the metastatic lung transfer of B16-F10 melanoma cells, presumably by inhibiting the expression of β1-integrin, a cell surface receptor that plays a key role in cell-matrix interaction (59).

Ginseng saponins are metabolized by intestinal bacteria and produce a variety of metabolites, which also exhibit anti-inflammatory and antimetastatic properties. For instance, compound K markedly attenuated the colony formation, adhesion and invasion of hepatocellular carcinoma (HCC) cells in vitro and markedly inhibited spontaneous HCC cell metastatic growth in vivo. This study also demonstrated that treatment with compound K diminished the nuclear accumulation of p65 and significantly reduced the expression of MMP-2 and MMP-9 (87). The intestinal bacterial metabolite of Rbl is 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (M1). The inhibition of spontaneous metastasis produced by the subcutaneous administration of Lewis lung carcinoma cells in syngenic C57BL/6 mice by Rbl has been reported to be the effect of its metabolite M1 (88). The anti-metastatic effect of this ginsenoside metabolite was comparable to that of the chemotherapeutic drug, 5-fluorouracil. Treatment with M1 inhibited the TNF-α-induced activation of NF-κB and reduced the expression of MMP-9, thereby suppressing the invasion and migration of colon adenocarcinoma cells. Moreover, the TNF-α-induced increase in lung and liver metastasis of colon carcinoma was also abrogated by treatment with M1 (89).

Chemosensitizing and radiosensitizing effects. Resistance to chemotherapy and radiotherapy is an emerging challenge in reducing the global burden of cancer. Attention has recently been paid to a wide variety of natural compounds which enhance the sensitivity of various resistant cancer cells to conventional chemotherapy and radiotherapy. Several ginsenosides and their intestinal bacterial metabolites have been reported to increase the chemosensitivity and radiosensitivity of cancer cells. Kim et al (90) investigated the effects of a combination of ginsenoside Rg3 with chemotherapeutic agents, such as docetaxel, paclitaxel, cisplatin and doxorubicin on the growth of colon cancer (SW480 and HCT-116) cells. Compared with treatment with individual chemotherapeutic agents or Rg3, the combination of each of the anticancer drugs with Rg3 elicited more pronounced anti-proliferative effects on these cells. Moreover, treatment with a combination of Rg3 and docetaxel induced apoptosis in these colon cancer cells by inhibiting the activity of NF-κB, inducing the expression of pro-apoptotic proteins (Bax, caspase-3 and -9) and decreasing the expression of anti-apoptotic proteins [Bcl-2, X-linked inhibitor of apoptosis (XIAP), inhibitor of apoptosis (IAP)1, COX-2 and cyclin D1], compared with the effects observed by treatment with docetaxel alone (90). The authors also demonstrated that Rg3 increased the susceptibility of human prostate cancer (LNCaP, PC3 and DU145) cells to docetaxel, cisplatin and doxorubicin. Compared to treatment with Rg3 or docetaxel alone, the combination treatment of Rg3 with docetaxel was more effective in the inhibition of prostate cancer cell growth and the induction of apoptosis, as well as G0/G1 cell cycle arrest accompanied by the significant inhibition of NF-κB activity (91). Likewise, in another study, the effects of combinations of Rh2 or its aglycon with docetaxel were predominantly additive or synergistic in PC3, DU145 and C4-2 prostate cancer cells. Combinations of Rh2 or its aglycon with docetaxel induced the regression of established PC3 tumors from their initial size by 15 and 27%, respectively, and reduced the expression of cell proliferation marker Ki-67 as compared with animals treated with docetaxel alone (92).

In a previous study, a combination of Rg3 and gemcitabine enhanced the growth-suppressive effect of gemcitabine in C57BL/6 mice bearing Lewis lung carcinoma cells and prolonged the survival of these tumor-bearing mice (15). Rg3 has been reported to enhance the penetration of paclitaxel into Caco-2 monolayer cells by downregulating the expression of p-glycoprotein (P-gp), also known as multidrug resistance protein-1 (MDRI), increasing the oral bioavailability of paclitaxel in rats. The enhancement of the oral bioavailability of paclitaxel by Rg3 was further established by the finding that the oral administration of a combination of paclitaxel and Rg3 attenuated the growth of MCF-7 breast cancer cell xenografts in nude mice more effectively than treatment with paclitaxel alone (93).

Resistance to chemotherapy is associated with the overexpression of the MDRI gene. Ginsenosides Rd, Re, Rbl and Rg1 have been shown to reduce the expression of MDRI in chemoresistant breast cancer (MCF7/ADR) cells. Further investigation with Rd ginsenoside revealed that Rd failed to alter the transcription of MDRI1 but induced the ubiquitin-dependent proteasomal degradation of MDRI1 and reversed the doxorubicin resistance of these cells (94). In another study, Rg3 potentiated the cytotoxic effects of cisplatin in CT-26 colon cancer cells by blocking the cisplatin-induced activation of Nrf2 and the expression of antioxidant enzymes HO-1 and NADPH:quinone oxidoreductase 1 (NQO1). In addition, the combination with Rg3 reduced the cytotoxic effects of cisplatin in normal LLC-RK1 kidney and NCTC1469 liver cells, suggesting that Rg3 is effective in relieving the renal and hepatic toxicity of cisplatin (95).

A synergistic inhibitory effect of ginsenoside Rh2 and cisplatin on the growth of a cell line (HRA) derived from ascites of a patient with serous cystadenocarcinoma of the ovary has been reported (96). According to the authors, Rh2
alone did not exhibit any significant growth inhibition of HRA cell xenographs in nude mice, but a combination of Rh2 with cisplatin induced a more pronounced inhibition of xenograft tumor growth, compared with treatment with cisplatin alone (96). Similarly, the treatment of LNCaP cell xenograft tumors with Rh2 plus paclitaxel has been shown to induce a significant decrease in tumor growth and serum PSA levels, suggesting a synergistic effect of Rh2 and paclitaxel (97). In another study, Rh2 induced apoptosis in multidrug-resistant human breast cancer cells by hypersensitizing these cells to paclitaxel. The apoptosis induced by Rh2 in combination with paclitaxel was mediated through the activation of glucocorticoid receptor, but not the expression of p53 or caspase-3 (98). Chae et al (99) reported that the treatment of NCI-H460 human lung cancer cells with compound K and simultaneous exposure to gamma-radiation resulted in the increased apoptosis of these cells through the generation of ROS and the activation of caspase-3. Moreover, the combination of compound K and gamma-ray led to the enhanced regression of NCI-H460 tumor xenographs in nude mice (99).

4. Future perspectives

The molecular target-based prevention of cancer has been widely accepted as a rational and practical strategy to reduce the global burden of cancer. A number of dietary phytochemicals have been reported to prevent cancer by targeting diverse intracellular signaling molecules implicated in the carcinogenic process. Extensively investigated ginseng and its vast array of saponins are attractive candidates for the development of chemopreventive and/or chemotherapeutic agents. As discussed in this review, studies on individual ginsenosides have revealed that many of them function through similar mechanisms by inhibiting growth or inducing apoptosis in cancer cells. Thus, it would be worthy to formulate a combination of ginsenosides, which would be multitargeting and may be more potent in preventing tumor growth. Such a formulation is KG-135, which is a mixture of ginsenosides Rk1, Rg3 and Rg5. The incubation of human mammary epithelial cells with KG-135 has been shown to inhibit the TPA-induced expression of COX-2 by blocking the activation of NF-κB and AP-1 (100). In another study, KG-135 diminished the proliferative ability of human prostate cancer (DU-145 and PC3) cells and reduced the growth of PC3 cell tumor xenografts in nude mice by inducing cell cycle arrest through the downregulation of cyclin D1 and Cdk expression (101). Moreover, KG-135 has been shown to enhance etoposide-induced apoptosis in HeLa cells by activating p53 and inducing the expression of Bax and p21 (102). These findings indicate that there is ample scope to develop novel ginsenoside formulations by mixing different types of ginsenosides. However, caution should be exercised before such attempts, as there have been reports that certain ginsenosides can promote tumor progression. For example, ginsenoside Rh2 has been shown to enhance the metastatic potential of BALB/c 3T3 cells in mice (103). Whereas the majority of ginsenosides inhibit inflammation, ginsenoside Rd has been shown to induce the expression of COX-2 and increase the production of PGE2 in Raw 264.7 macrophages by enhancing the DNA binding of C/EBP and cyclic-AMP response element binding protein (CREB) (104). Therefore, the combination of ginsenosides in the development of novel formulas for chemoprevention and/or chemotherapy must be carried out judiciously so that the overall therapeutic benefit may be best achieved.

A few studies have demonstrated the prolongation of survival and improvement of quality of life in cancer patients receiving ginseng or its component, ginsenoside Rg3 (105,106). Kim et al (105) reported that a 12-week therapy with ginseng improved the mental and physical health of patients diagnosed with gynecological cancer and hepatobiliary cancer. The administration of ginsenoside Rg3 together with chemotherapy has also been shown to increase the post-surgical life span of patients suffering from non-small cell lung cancer (106). These limited clinical experiences and extensive preclinical study outcomes indicate the potential of ginsenosides or their formulations in cancer prevention and therapy. Further clinical trials with ginsenosides or their combinations, and extensive pharmacokinetic studies are required to perform dosage adjustment and to achieve bioavailable doses of ginsenosides. It should also be taken into consideration that ginsenosides, when administered by gavage, can undergo intestinal metabolism, which often produces active metabolites. Thus, more rigorous studies in terms of bioavailability, metabolism and dose-response relationships would make this age-old oriental medicine exploitable for cancer chemoprevention and/or chemotherapy.

Acknowledgements

This study was supported by the Settlement Research Grant-2012-0195 of Keimyung University allocated to Joydeb Kumar Kundu.

References


